Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.36 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.33 |
| ▸ | QDPR | P09417 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.30 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4283465 | 0.83 | MEN1 (0.45) | HSD11B1 | |
| SCHEMBL4289135 | 0.78 | DRD2 (0.37) | — | |
| SCHEMBL1634692 | 0.75 | CYP11B2 (0.41) | KDM1A | |
| SCHEMBL5591941 | 0.70 | HTR2C (0.38) | KDM1A | |
| SCHEMBL10596489 | 0.68 | ESR1 (0.40) | — | |
| SCHEMBL9580351 | 0.67 | ESR2 (0.46) | — | |
| SCHEMBL18262830 | 0.66 | QDPR (0.52) | QDPRTSHRCASP1KDM1A | |
| SCHEMBL1383876 | 0.65 | ANPEP (0.39) | TSHR | |
| SCHEMBL2183528 | 0.65 | PDPK1 (0.37) | TSHR | |
| SCHEMBL5715615 | 0.64 | POLB (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090176307-A1 | Compounds, Compositions and Methods | CYTOKINETICS, INC. | 2009-07-09 | — | — | US | disclosed |
| US-7491826-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-7399866-B2 | Compounds, compositions, and methods | CYTOKINETICS, INC. (US) | 2008-07-15 | — | — | US | disclosed |
| US-20060241110-A1 | Compounds, compositions, and methods | CYTOKINETICS, INCORPORATED | 2006-10-26 | — | — | US | disclosed |
| US-20050159416-A1 | Compounds, compositions and methods | CYTOKINETICS, INCORPORATED | 2005-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241110-A1 | Compounds, compositions, and methods | TNNI3, TNNT2, TNNC1 | HSD11B1 4305/4885PFKFB3 2445/4885QDPR 2233/4885 |
| US-20050159416-A1 | Compounds, compositions and methods | TNNI3, TNNC1, TNNT2 | HSD11B1 4322/4885PFKFB3 2399/4885QDPR 2401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.